Several other analysts have also issued reports on SHP. Deutsche Bank AG reissued a buy rating and set a GBX 5,600 ($73.10) price target on shares of Shire PLC in a report on Tuesday, May 31st. Credit Suisse Group AG restated an outperform rating and issued a GBX 5,000 ($65.27) price objective on shares of Shire PLC in a research report on Wednesday, June 1st. JPMorgan Chase & Co. reiterated an overweight rating and issued a GBX 5,600 ($73.10) target price on shares of Shire PLC in a research report on Wednesday, June 1st. Morgan Stanley reiterated an overweight rating and issued a GBX 5,600 ($73.10) target price on shares of Shire PLC in a research report on Friday, June 3rd. Finally, Jefferies Group boosted their target price on Shire PLC from GBX 5,150 ($67.22) to GBX 6,050 ($78.97) and gave the stock a buy rating in a research report on Monday, June 6th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average price target of GBX 5,828 ($76.07).
Shares of Shire PLC (LON:SHP) opened at 5040.00 on Wednesday. Shire PLC has a 12-month low of GBX 2,707.19 and a 12-month high of GBX 5,377.00. The stock’s market cap is GBX 34.41 billion. The firm has a 50 day moving average price of GBX 4,983.22 and a 200 day moving average price of GBX 4,511.67.
The business also recently announced a dividend, which will be paid on Friday, October 7th. Investors of record on Thursday, September 8th will be issued a GBX 3.51 ($0.05) dividend. The ex-dividend date is Thursday, September 8th. This represents a yield of 0.07%.
In other Shire PLC news, insider Dominic Blakemore purchased 133 shares of the company’s stock in a transaction on Friday, September 30th. The stock was acquired at an average price of GBX 5,010 ($65.40) per share, for a total transaction of £6,663.30 ($8,697.69).
About Shire PLC
Shire plc is a biotech company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other select conditions. The Company operates in the segment of research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.